Antonio La Cava, M.D., Ph.D.

Business address: 1000 Veteran Ave. 32-59 Los Angeles, CA 90095-1670 Tel. (310) 267-4975 Fax: (310) 206-8606 E-mail: alacava@mednet.ucla.edu Antonio La Cava, M.D., Ph.D. Home address: 1145 11 th St. Santa Monica, CA, 90403 Tel. (310) 382-4538 Antonio La Cava, M.D., Ph.D. Personal data Education Professional Experience Teaching Born on December 10, 1960, in Monza, Italy Permanent resident in the USA April 14, 1989: M. D. summa cum laude, School of Medicine, "Federico II" University of Naples, Italy October 17, 1995: Ph.D. in Cellular and Molecular Biology and Pathology, "Federico II" University of Naples, Italy 2009-present: Director of the University of California Los Angeles Center of Excellence for the Federation of Clinical Immunology Societies 2009: Professor, Department of Medicine, University of California Los Angeles 2005-present: Director of the University of California Los Angeles Lupus Research Laboratory 2005-2009: Associate Professor, Division of Rheumatology, Department of Medicine, University of California Los Angeles 2001-2005: Assistant Professor, Division of Rheumatology, Department of Medicine, University of California Los Angeles 1998 2001: Research Associate, Department of Immunology, The Scripps Research Institute, La Jolla, California 1993-1997: Postgraduate Research Immunologist, Department of Medicine, University of California San Diego 1989-1993: Postdoctoral Fellow, Department of Cellular and Molecular Biology and Pathology, School of Medicine, "Federico II" University of Naples, Italy 1987-1989: Research Assistant, Department of Cellular and Molecular Biology and Pathology, School of Medicine, "Federico II" University of Naples, Italy 1992-1993: Lecturer of Immunology, School of Pharmacy, "Federico II" University of Naples, Italy 1

Professional Activities COMMITTE SERVICES Graduate Division Committee, University of California Los Angeles GRANTS Member: Alliance for Lupus Research (ALR): 2009-2011 National Institutes of Health (NIH): 2011-2014 Ad hoc: National Institutes of Health HAI Study Section: 2006.II 2007.III 2008.I 2008.III 2009.I 2010.I 2010.II ACTS Study Section: 2007.I 2007.II Special Emphasis Panels: ZAI1 KS-I M1, 2006.I ZAI1 IMM-E 58R, 2009-10 ZRG1 IDM-C 58R, 2009-10 ZRG1 MOSS-G 03M, 2009.II ZRG1 MOSS-G 96R, 2009.II ZRG1 IMM-E 55R, 2010-08 Other Domestic: ALR, 2008 Arthritis Foundation, 2008-present Lupus Foundation of America, 2007-present Arizona Biomedical Research Commission, 2007-present Barrow Neurological Institute, 2007-present Other Foreign: European Commission Research Directorate General Medical Research Council (UK) The Wellcome Trust (UK) Health Research Board (Ireland) Catalan Agency for Health Technology Assessment and Research (Spain) Italian National Research Council (Italy) Italian Ministry of Education, University and Research (Italy) Austrian Science Fund (Austria) 2

Israel Science Foundation The Agency for Science, Technology and Research s Biomedical Research Council (Singapore) JOURNALS Editorial Board: Journal of Clinical Investigation Journal of Immunology Frontiers in Biosciences Autoimmunity Immunopharmacology and Immunotoxicology BioMedCentral Musculoskeletal Disorders Recent Patents on Inflammation & Allergy Drug Discovery Current Bioactive Compounds International Journal of Clinical and Experimental Medicine Journal of Pediatric Biochemistry Ad hoc Reviewer: American Journal of Pathology Annals of Neurology Archives of Immunology & Ther Exp Arthritis & Rheumatism Arthritis Research & Therapy Biochimie BMC Immunology Cellular & Clinical Endocrinology Cellular Immunology Clinical Chimica Acta Clinical Endocrinology Clinical Experimental Immunology Clinical Experimental Rheumatology Clinical Rheumatology Clinical Medicine: Dermatology Current Immunology Review Current Pharmaceutical Design Cytokine Cytotherapy Endocrine-Related Cancer European Journal of Internal Medicine Experimental Biology & Medicine Experimental Neurology Expert Review Vaccines FASEB Journal Genes & Immunity Human Immunology Journal of Applied Physiology 3

Journal of Biomedicine and Biotechnology Journal of Cell Physiology Journal of Clinical Immunology Journal of Immunological Methods Journal of Leukocyte Biology Journal of Molecular Cell Biology Journal of Molecular Medicine Journal of Neuroimmunology Immunology Letters International Journal of General Medicine Lupus Mayo Clinic Proceedings Mediators of Inflammation Medicine Principles Practice Molecular Biology Reports Nature Reviews in Rheumatology PLoS ONE Rheumatology (Oxford) Scandinavian Journal of Immunology Scandinavian Journal of Rheumatology Trends in Cardiovascular Medicine Trends in Immunology BOOKS Oxford University Press Bentham Science Publishers Academic Press (UK) PROFESSIONAL ASSOCIATIONS AND SCHOLARLY SOCIETIES Henry Kunkel Society American College of Rheumatology (ACR) American Association of Immunologists (AAI) Federation of American Societies for Experimental Biology (FASEB) American Association for the Advancement of Science (AAAS) International Union of Immunological Societies (IUIS) Selection of Abstracts 2007, 2008, 2009, 2010: ACR Abstract Selection Subcommittee 2009, 2010: FOCiS Abstract Selection Committee 2010: Western Society of Clinical Investigation Honors and Awards 2008: James Klinenberg Award of Excellence in Research, Arthritis Foundation 2008: FOCIS Prize of Distinction 2007: Roche Award for Research Excellence 2007: FOCIS Travel Award 4

2007: Best Oral Presentation, 8 th International Lupus Meeting 2006: Henry Kunkel Society. 2006: FOCIS Travel Award 2004: Stein Oppenheimer Award 2004: International Congress of Immunology Travel Award (NIH-NIAID sponsored) 2004: Who Is Who in Medicine, Academic Keys 2002: Henry Christian Award for Excellence in Clinical Research, American Federation for Medical Research (AFMR), Beverly, MA 2002: Global Arthritis Research Network (GARN) Travel Award. Research Papers (past five years) PUBLICATION/BIBLIOGRAPHY 1. Vollmer T.L., Liu R., Price M., Rhodes S., La Cava A., Shi F.-D. 2005. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 174: 2696-2701. 2. Matarese G., Carrieri P.B., La Cava A., Perna F., Sanna V., De Rosa V., Aufiero D., Fontana S., Zappacosta S. 2005. Leptin increase in multiple sclerosis associates with reduced number of CD4 + CD25 + regulatory T cells. Proc. Natl. Acad. Sci. USA 102:5150-5155. 3. Hahn B.H., Singh R.P., La Cava A., Ebling F. 2005. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosisresistant, TGFβ-secreting CD8 + T cell suppressors. J. Immunol. 175:7728-7737. 4. Liu R., La Cava A., Bai X.-F., Jee Y., Price M., Campagnolo D.I., Christadoss P., Vollmer T.L., Van Kaer L., Shi F.-D. 2005. Cooperation of invariant NKT cells and CD4 + CD25 + T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 175:7898-7904. 5. De Rosa V., Procaccini C., La Cava A., Chieffi P., Nicoletti G.F., Fontana S., Zappacosta S., Matarese G. 2006. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J. Clin. Invest. 116: 447-455. 6. Liu R., Van Kaer L., La Cava A., Price M., Campagnolo D.I., Collins M., Young D.A., Vollmer T.L., Shi F.-D. 2006. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J. Immunol. 176:5247-5254. 7. Ferrera F, Hahn BH, Rizzi M, Anderson M, FitzGerald J, Millo E, Indiveri F, Shi F-D, Filaci G, La Cava A. 2007. Protection against renal disease in (NZB x NZW)F 1 lupus mice after somatic B cell gene vaccination with anti-dna immunoglobulin consensus peptide. Arthritis Rheum. 56:1945-1953. 8. De Rosa V, Procaccini C, Calì G, Pirozzi G, Fontana S, Zappacosta S, La Cava 5

A, Matarese G. 2007. A key role for leptin in the control of regulatory T cell proliferation. Immunity 26:241-255. 9. Singh RP, La Cava A, Wong M, Ebling F, Hahn BH. 2007. CD8 + T cellmediated suppression of autoimmunity in a murine lupus model of peptideinduced immune tolerance depends on Foxp3 expression. J. Immunol. 178:7649-7657. 10. Feng X, Li H, Rumbin AA, Wang X, La Cava A, Brechtelsbauer K, Castellani LW, Witztum JL, Lusis AJ, Tsao BP. 2007. ApoE -/- Fas -/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis and osteopenia. J. Lipid Res. 48:794-805. 11. Piao W-H, Jee YH, Liu RL, Coons SW, Kala M, Collins M, Young DA, Campagnolo DI, Vollmer TL, Bai X-F, La Cava A, Shi F-D. 2007. IL-21 modulates CD4 + CD25 + regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 67:37-46. 12. Singh RP, La Cava A, Hahn BH. pconsensus peptide induces tolerogenic CD8 + T cells in lupus-prone (NZB x NZW)F 1 mice by differentially regulating Foxp3 and PD1 molecules. J. Immunol. 180:2069-80. 13. Liu R, Bai Y, Vollmer TL, Bai X-F, Jee Y, Tang Y-Y, Campagnolo DI, Collins M, Young DA, La Cava A, Shi F-D. 2008. IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. Exp. Neurol. 211:14-24. 14. Bai Y, Liu R, Huang D, La Cava A, Tiang YY, Iwakura Y, Campagnolo DI, Vollmer TL, Ransohoff RM, Shi F-D. 2008. CCL2 recruitment of IL-6- producing CD11b + monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur. J. Immunol. 38:1877-1888. 15. Hahn BH, Anderson M, Le E, La Cava A. 2008. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum. 58:2488-2497. 16. Fenoglio D, Ferrera F, Fravega M, Balestra P, Battaglia F, Proietti M, Andrei C, Olive D, La Cava A, Indiveri F, Filaci G. 2008. Advancements on phenotypic and functional characterization of non-antigen specific CD8 + CD28 - regulatory T cells. Hum. Immunol. 69:745-750. 17. Wong M, Grossman J, Hahn BH, La Cava A. 2008. Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin. Immunol. 129:3-9 (featured on front cover). 18. Agrawal A, Lourenço EV, Gupta S, La Cava A. 2008. Gender-based differences in leptinemia in healthy aging, non-obese individuals associate with 6

increased marker of oxidative stress. Int. J. Clin. Exp. Med. 1:305-309. 19. Lourenço EV, Procaccini C, Ferrera F, Iikuni N, Singh RP, Filaci G, Matarese G, Shi F-D, Brahn E, Hahn BH, La Cava A. 2009. Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-dna Ig peptide in (NZB x NZW)F 1 lupus mice. J. Immunol. 182: 7415-7421. 20. Iikuni N, Lourenço EV, Hahn BH, La Cava A. 2009. Cutting edge: Regulatory T cells directly suppress B cell in systemic lupus erythematosus. J. Immunol. 183: 1518-1522. 21. Singh RP, Dinesh R, Elashoff D, De Vos S, Rooney RJ, Patel D, La Cava A, Hahn BH. 2010. Distinct gene signature revealed in white blood cells, CD4 + and CD8 + T cells in (NZB x NZW) F 1 lupus mice after tolerization with anti-dna Ig peptide. Genes Immun. 11:294-309. 22. Liu R, Piao W, Campagnolo DI, Vollmer TI, La Cava A, Shi F-D. 2010. Expansion of CD4 + CD25 + regulatory T cells via IL-2/anti-IL-2 mab complexes restores immune tolerance to autoantigens. Eur. J. Immunol. 29:1577-89. 23. Woo JM, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo KM, Li H, Castellani LW, Wang X, Iikuni N, Rullo OJ, Wu H, La Cava A, Fogelman AM, Lusis AJ, Tsao BP. 2010. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther. 18:R93. 24. Hahn BH, Lourenço EV, McMahon M, Skaggs B, Le E, Anderson M, Iikuni N, Lai CK, La Cava A. Pro-Inflammatory high density lipoproteins (pihdl) and atherosclerosis are induced in lupus-prone mice by high fat diet and leptin. Lupus In press Book chapters 1. La Cava A. 2008. Antibodies to DNA in systemic lupus erythematosus: A review and update. In Petrelli CT (Ed.): New research on autoantibodies. Nova Science Publishers, New York. pp. 61-86. 2. La Cava A, Hahn BH. 2008. Immunotherapy with Ig-derived peptides in SLE: Current status and directions. In Seward TI (Ed.): Progress in systemic lupus erythematosus research. Nova Science Publishers, New York. pp. 131-153. 3. La Cava A. 2008. Regulatory T cells. In Pontell EB (Ed.): Immune Tolerance Research Developments. Nova Science Publishers, New York. pp. 51-74. 4. Iikuni N, La Cava A. 2009. Murine models of lupus for the study of human SLE. In La Cava A. (Ed.): Recent research developments in rheumatology. Research Signpost, Trivandrum, pp. 55-78. 5. La Cava A. 2009. New developments in the management of systemic lupus 7

erythematosus. In La Cava A. (Ed.): Recent research developments in rheumatology. Research Signpost, Trivandrum, pp. 79-97. 6. Hahn BH, Singh RR, Singh RP, Wong M, Skaggs B, Tsao BP, La Cava A. 2009. Cellular regulation of autoimmunity. In Pisetsky D (Ed.): The American College of Rheumatology at 75: A diamond jubilee. John Wiley & Sons, Inc., Hoboken, pp 125-131. 7. La Cava A. Immunotherapy with synthetic peptides in systemic lupus erythematosus. In Immunotherapy: activation, suppression and treatments. Nova Science Publishers, Hauppauge (New York). In press. Reviews 1. Hahn B.H., Ebling F., Singh R.R., Singh R.P., Karpouzas G., La Cava A. 2005. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann. N. Y. Acad. Sci. 1051:433-441. 2. La Cava A., Fang C., Singh R.P., Ebling F., Hahn B.H. 2005. Manipulation of immune regulation in murine systemic lupus erythematosus. Autoimmun. Rev. 4:515-519. 3. Matarese G., La Cava A. 2005. Immune responses in obesity models. Drug Discov. Today 2:177-181. 4. La Cava A., Shi F.-D. 2006. Natural and adaptive immune cell-based therapies in autoimmunity. Curr. Med. Chem. 13:1557-1566. 5. La Cava A., Van Kaer L., Shi F.-D. 2006. CD4 + CD25 + Tregs and NKT cells: regulators regulating regulators. Trends Immunol. 27:322-327. 6. Matarese G, Leiter EH, La Cava A. 2007. Leptin in autoimmunity: many questions, some answers. Tissue Antigens 70:87-95. 7. Ferrera F, La Cava A, Rizzi M, Hahn BH, Indiveri F, Filaci G. 2007. Gene vaccination for the induction of immune tolerance. Ann. N. Y. Acad. Sci. 1110:99-111. 8. Matarese G, Mantzoros C, La Cava A. 2007. Leptin and adipocytokines: the gap between immunity and atherosclerosis. Curr. Pharm. Des. 13:3676-3680. 9. Ferrera F, Filaci G, Rizzi M, Singh RP, Indiveri F, Hahn BH, La Cava A. 2008. New therapies in SLE. Recent Patents Inflamm. Allergy Drug Disc. 2:11-23. 10. Gianfrani C, Troncone R, La Cava A. 2008. Autoimmunity and celiac disease. Mini Rev. Med. Chem. 8: 129-134. 11. Matarese G, De Rosa V, La Cava A. 2008. Regulatory CD4 T cells: sensing the environment. Trends Immunol. 29:12-17. 8

12. La Cava A. 2008. Natural Tregs in systemic lupus erythematosus. Curr. Immunol. Rev. 4:11-19. 13. La Cava A. 2008. T-regulatory cells in systemic lupus erythematosus. Lupus 17:421-425. 14. Iikuni N, Lam QL, Lu L, Matarese G, La Cava A. 2008. Leptin and inflammation. Curr. Immunol. Rev. 4:70-79. 15. Singh RP, Hahn BH, La Cava A. 2008. Tuning immune suppression in systemic autoimmunity with self-derived peptides. Inflamm Allergy Drug Targets 7:253-259. 16. La Cava A. 2008. Tregs are regulated by cytokines: Implications for autoimmunity. Autoimm. Rev. 8:83-87. 17. Procaccini C, Lourenço EV, Matarese G, La Cava A. 2009. Leptin signaling: A key pathway in immune responses. Curr. Signal Transduct. Ther. 4:22-30. 18. La Cava A. 2009. Natural Tregs and autoimmunity. Front. Biosci. 14:333-343. 19. Iikuni N, Hahn BH, La Cava A. 2009. Potential for anti-dna immunoglobulin peptide therapy in systemic lupus erythematosus. Exp. Opin. Biol. Ther. 9:201-206. 20. La Cava A. 2009. Immunotherapy with peptides in systemic lupus erythematosus. Curr. Med. Chem. 16: 1482-1488. 21. Lourenço EV, La Cava A. 2009. Cytokines in systemic lupus erythematosus. Curr. Mol. Med. 9:242-254. 22. La Cava A. 2009. Lupus and T cells. Lupus 18:196-201. 23. Cai C, La Cava A. 2009. Mimicking self antigens with synthetic peptides in systemic autoimmune rheumatic diseases. Curr. Clin. Pharmacol. 4:142-147. 24. Iikuni N, La Cava A. 2009. Antibody-based therapies in systemic lupus erythematosus. Mini Rev. Med. Chem. 9: 829-846. 25. Cai C, Hahn BH, Matarese G, La Cava A. 2009. Leptin in non-autoimmune inflammation. Inflamm. Allergy Drug Targets 8:285-291. 26. La Cava A. 2009. The busy life of regulatory T cells in systemic lupus erythematosus. Discov. Med. 8:13-17. 27. Cai C, Shi F-D, Matarese G, La Cava A. 2009. Leptin as clinical target. 9

Recent Pat. Inflamm. Allergy Drug Discov. 3:160-166. 28. Galgani M, Di Giacomo A, Matarese G, La Cava A. 2009. The yin and yang of CD4 + regulatory T cells in autoimmunity and cancer. Curr. Med. Chem. 16:4626-4631. 29. Dinesh RK, Skaggs BJ, La Cava A, Hahn BH, Singh RP. 2010. CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun. Rev. 9:560-568. 30. La Cava A. Modulation of autoimmunity with artificial peptides. Autoimmun. Rev. In press. 31. Lourenço EV, La Cava A. Natural CD4 + regulatory T cells in autoimmunity. Autoimmunity In press. Editorials 1. Update on the Pathogenesis of Immune Dysregulation in Autoimmunity. La Cava A. (Ed.). 2008. Frontiers in Bioscience, Albertson, NY. 2. Recent Research Developments in Rheumatology. La Cava A. (Ed.). 2009. Research Signpost, Trivandrum. 3. Immunoregulatory cell subsets in autoimmunity. La Cava A. (Ed.). Informa Healthcare, New York. In press. 10